Melanoma Clinical Trials

Showing 661-680 of 705 trials

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

NCT00077532

RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Vaccines made from gp100 peptides may make the body build an immune response to kill tumor cells. Combining the vaccines with Montanide ISA-51 may cause a stronger immune response and kill more tumor cells. It is not yet known whether monoclonal antibody therapy is more effective with or without vaccine therapy in treating advanced melanoma. PURPOSE: This randomized phase II trial is studying monoclonal antibody therapy alone to see how well it works compared to monoclonal antibody therapy, gp100 peptides, and Montanide ISA-51 in treating patients with stage IV melanoma.

Melanoma (Skin)

National Institutes of Health Clinical Center (CC)179 participantsStarted Mar 2004

Bethesda, Maryland, United States

COMPLETEDPHASE2

Study of CP-675,206 in Refractory Melanoma

NCT00254579

CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.

Refractory Melanoma

AstraZeneca251 participantsStarted Dec 2005

Scottsdale, Arizona, United States • Bentonville, Arkansas, United States • Fayetteville, Arkansas, United States +62 more locations

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

Study of CP-675,206 in Refractory Melanoma

Related Searches

Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma

CP-675,206 In Patients With Advanced Melanoma

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

A Study of Volociximab in Metastatic Melanoma

Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma

Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

CP-461 in the Treatment of Patients With Advanced Melanoma

Study of XL281 in Adults With Solid Tumors

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma